Notícias e Atividades da Akari Therapeutics
Executivos
Veja o organograma con seus 12 executivos principais
Biografias mais buscadas da Akari Therapeutics
- Samir Patel, Chief Executive Officer (until Apr 21 2025)
- Abizer Gaslightwala, President and Chief Executive Officer (starts...
- Sandip Patel, Director
Recentes movimentos de executivos em Akari Therapeutics
- Samir Patel, Chief Executive Officer, deixará a Companhia em 21 de abr. de 2025 (Notícia publicada em 21 de março de 2025).
- Abizer Gaslightwala ingressará na Companhia como President and Chief Executive Officer em 21 de abr. de 2025 (Notícia publicada em 21 de março de 2025).
- Samir Patel antes Interim Chief Executive Officer & Director, agora é Chief Executive Officer (Notícia publicada em 19 de dezembro de 2024).
Clique aqui para ver outras movimentos em Akari Therapeutics
Criar um alerta
para seguir os movimentos de executivos da Akari Therapeutics.
Biotecnologia
Akari Therapeutics possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).
Popular M&A news in Biotecnologia
- Transcarent and Accolade have merged (publicado em 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
- Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Akari Therapeutics
- Akari Therapeutics Narrows Pipeline Focus | Akari Therapeutics
- Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy | Akari Therapeutics
- Press Releases | Akari Therapeutics
- Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress | Akari Therapeutics
- Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) | Akari Therapeuti
- Press Releases | Akari Therapeutics
- Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies | Akari Therapeutics
- Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting | Akari Therapeutics
- Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress | Akari Therapeutics
- Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting | Akari Therapeutics
- View more press releases Close
Redes sociais sobre Akari Therapeutics
- Akari Therapeutics na Wikipedia, Google News e Yahoo Finance
- Akari Therapeutics na LinkedIn, Twitter e YouTube
